I'm just reposting this post of mine from Stockhouse so that I can more easily track it down in the future.

-------------------------------------------

We don't know for sure what the xB3-007 trial is at this point. Undisclosed neurodegeneration program. Presumably not Parkinson's since that was referred to as xB3-003. The MD&A only stated "Advance Our xB3-007 Program Targeting Neurodegenerative Diseases. We will provide further details on this program going forward based on future developments and progress, as appropriate."

Back in the June 14, 2017 letter to shareholders, Mark Day stated "Several significant breakthroughs were made in the last year. The most exciting for me was with Alzheimer’s disease. Biogen demonstrated their aducanumab could slow the progression of Alzheimer’s disease in mild-to-moderate patients. This truly was a first and shows that when you prioritize science, you can yield truly astounding results."

Clearly, Mark Day is excited about Biogen/Aducanumab/Alzheimer's disease. There have been lots of failed anti-amyloid beta Alzehimer's trials to date. Various reasons for failiure (patient population, severity of disease, antibody target, etc). All of those are important variables. But maximizing transport of those amyloid beta antibodies across the blood brain barrier could really be a factor here. I know, duh....why do you think the xB3-001 program is so important? But for anyone who follows Alzheimer's amyloid beta antibody trials, does the inefficiency of BBB transport of those antibodies ever come up?

On a side note, G1945V and I had a little chat about ProMIS Neurosciences. They have what they think is an improved antibody for specifically targeting the amyloid-B oligomers and not so much the monomers or plaques. Whether or not their hypothesis that targeting these oligomers, as opposed to antibodies that also have high affinity for the monomers or plaques like Aducanumab, will prove itself in trials will take a long time. ProMIS has yet to start Phase 1 and Biogen's Phase 3 with Aducanumab is set to read out 2020. 

Anyways, if anyone is interested in a great overview of amyloid beta antibody Alzheimer's trials, this video from ProMIS earlier this week gives a great overview of past, current and future trials. Thanks for sharing with me G1945V!

BearDownAZ